Novo Nordisk (NVO) is attempting to prevent Eli Lilly (LLY) from sharing clinical trial results, Lilly has stated. Lilly's characterization: NVO is choosing to limit disclosure rather than compete on the merits. The accusation draws a public line between the two companies over how trial results reach the market.
The allegation
Lilly's statement targets one specific conduct: NVO working to stop Lilly from releasing trial data. Lilly did not describe NVO as generating better results or outpacing it on trial timelines. The characterization is of obstruction, not outperformance.
What the source does not establish
No specific trial or drug is named. No filing or dollar figure appears in Lilly's statement. The market has nothing numerical to reprice at this stage. What is on record is Lilly's stated position: NVO moved to restrict what Lilly can share, and Lilly chose to say so publicly.